Satellos Bioscience Inc Stock Price, News & Analysis

Satellos Bioscience (OTCQB: MSCLF) reported positive Phase 1b results for SAT-3247 in treating Duchenne muscular dystrophy (DMD). The trial demonstrated safety and an approximate doubling in grip strength in five adult DMD patients after 28 days of treatment.

The company plans to initiate a follow-up study in Q3 2025, with 3-month interim data expected by year-end. Satellos is also preparing for a global Phase 2 randomized trial in children with DMD, pending regulatory approvals.

Financially, Satellos ended Q2 2025 with $38.2 million in cash, reporting a net loss of $5.6 million ($0.03 per share) compared to $4.4 million ($0.04 per share) in Q2 2024. R&D expenses increased to $4.4 million from $3.6 million year-over-year.

Satellos Bioscience (OTCQB: MSCLF), a clinical-stage biotech company focused on developing treatments for degenerative muscle diseases, has announced its participation in the Canaccord Genuity's 45th Annual Growth Conference. The event will take place on August 13-14, 2025, at the InterContinental Boston.

Management will deliver a presentation on Wednesday, August 13, from 12:30 to 12:55 p.m. ET in Abigail Adams C and will be available for one-on-one meetings. Investors can access the live webcast through the Events and Presentations page in the Investors section of Satellos' website, with a replay available after the event.

Satellos Bioscience (OTCQB: MSCLF) has appointed Dr. Wildon Farwell as Chief Medical Officer to advance their muscle disease therapeutic programs. Dr. Farwell joins from Dyne Therapeutics, where he served as CMO and brings significant expertise in neuromuscular disease drug development.

Dr. Farwell's notable achievements include building Dyne's development organization and leading their DMD and DM1 programs. At Biogen, he led the development of SPINRAZA®, the first approved treatment for spinal muscular atrophy, and initiated late-stage development of QALSODY® for ALS.

In his new role, Dr. Farwell will focus on advancing SAT-3247 into a global Phase 2 clinical trial for children with Duchenne muscular dystrophy (DMD). He succeeds Dr. Jordan Dubow, who will continue as a consultant and Clinical Advisory Board chair.

[ "Appointment of highly experienced CMO with proven track record in neuromuscular disease drug development", "New CMO has successful history of regulatory approvals, including SPINRAZA®", "Progress toward Phase 2 clinical trial for SAT-3247 in DMD treatment" ]

Satellos Bioscience (MSCLF) has elected two new board members, Dr. Iris Loew-Friedrich and Dr. Selwyn Ho, bringing significant expertise in clinical development and commercial strategy. Dr. Loew-Friedrich, former EVP and CMO at UCB, led global development and regulatory strategies resulting in multiple blockbuster therapy approvals. Dr. Ho brings extensive experience in commercial strategy and business development, having held senior roles at companies like Dermira, UCB, and Allergan. As CEO of Medigene AG, he led strategic partnerships and raised over $350M through IPO and private funding. Three board members - Dr. Rima Al-awar, William Jarosz, and Dr. William McVicar - did not seek reelection. The appointments come as Satellos advances its SAT-3247 program for Duchenne muscular dystrophy treatment.

Satellos Bioscience (MSCLF) held its Annual and Special Meeting of Shareholders on June 18, 2025, with 41.15% of outstanding shares represented. All nominated directors were successfully elected with over 97% approval rates. The most notable outcome was shareholders' approval of a potential reverse stock split ranging from 1-for-5 to 1-for-15, subject to Board implementation. The exact ratio and effective date will be announced later if the Board proceeds. Shareholders also approved PricewaterhouseCoopers LLP's reappointment as auditors. The meeting demonstrated strong shareholder support for the company's leadership, with directors receiving approval rates between 97.41% and 99.99%.

Satellos Bioscience (MSCLF) announced its participation in the 2025 Parent Project Muscular Dystrophy (PPMD) Annual Conference, scheduled for June 19-21 in Las Vegas. The conference brings together families, researchers, clinicians, and companies focused on improving outcomes for Duchenne patients. Satellos, a biotech company developing small molecule therapeutics for muscle diseases, will engage with the Duchenne community and share updates on their scientific approach to regenerate muscle from within. The company will maintain a presence at the exhibition hall where attendees can meet team members and learn more about their work.

Satellos Bioscience (MSCLF) reported Q1 2025 financial results and progress updates for its DMD drug candidate. The company completed enrollment in its Phase 1b trial for SAT-3247 in adult Duchenne muscular dystrophy patients, with data expected in Q2 2025. The drug demonstrated safety and tolerability in Phase 1a trials. Satellos received approval for an 11-month follow-up study and plans to submit global regulatory filings for a Phase 2 pediatric trial in Q3 2025. Financially, the company reported cash position of $41.2M as of March 31, 2025, down from $48.5M in December 2024. Q1 2025 net loss widened to $6.1M ($0.04/share) compared to $5.1M ($0.05/share) in Q1 2024, due to increased R&D and G&A expenses. The company changed its reporting currency to USD effective January 2025.

Satellos Bioscience Inc. (MSCLF), a clinical-stage biotech company focused on developing treatments for degenerative muscle diseases, has announced its participation in the CureDuchenne FUTURES National Conference in San Antonio, TX. The event will take place from May 22-25, 2024. Company Co-founder and CEO Frank Gleeson will be presenting during the "New Therapeutic Approaches" session on May 24 from 1:30-2:30 p.m. CT.

Satellos Bioscience (TSX: MSCL, OTCQB: MSCLF), a clinical-stage biotech company focused on developing treatments for degenerative muscle diseases, has announced its participation in the upcoming 2025 Bloom Burton & Co. Healthcare Investor Conference in Toronto.

Key details:

• Event Date: May 5-6, 2025
• Presentation Time: 11:30 a.m. ET on May 5
• Location: Metro Toronto Convention Centre
• Presenter: Frank Gleeson, Co-founder and CEO

The company will offer both a presentation and webcast format, with management participating in one-on-one meetings during the conference. Investors can access the live webcast through Satellos' website's Investors section, with a replay available post-presentation.